Alglucosidase Alfa (Myozyme and Lumizyme)

Alglucosidase alfa is a recombinant enzyme-replacement drug for Pompe disease, a rare inherited disorder in which a missing enzyme lets glycogen build up inside muscle cells, including the heart — untreated, its infantile-onset form kills the large majority of babies before their first birthday. Approved in 2006 as the first disease-specific Pompe treatment, the same molecule was approved a second time in 2010 under a different brand name, Lumizyme, because manufacturing it at a larger production scale counted as a distinct product to the FDA — and that second approval initially came with a restricted-use program limiting it to older patients, not lifted until 2014.

A disease that was uniformly fatal in infancy

Pompe disease is a rare inherited disorder caused by deficient activity of acid alpha-glucosidase (GAA), an enzyme that normally breaks down glycogen inside lysosomes. Without it, glycogen accumulates inside muscle cells throughout the body, most dangerously in the heart and the muscles used for breathing. In its most severe form, classic infantile-onset Pompe disease, progressive heart enlargement and muscle weakness typically caused death from cardiorespiratory failure within the first year of life in the large majority of untreated infants, well before enzyme-replacement therapy existed. A milder, later-onset form can present at any age from childhood to adulthood, progressing more slowly but still causing disabling respiratory and skeletal-muscle weakness over years. The drug that changed this outcome has a genuinely personal origin story: John Crowley, a father whose two youngest children were diagnosed with Pompe disease as infants, left a pharmaceutical marketing career to co-found Novazyme Pharmaceuticals with glycobiologist William Canfield in 2000, working specifically on an improved recombinant GAA enzyme; Genzyme acquired Novazyme in 2001 and continued that development program with Crowley in a leadership role, a story later dramatized in the 2010 film Extraordinary Measures. Genzyme's resulting drug, alglucosidase alfa — produced in genetically engineered Chinese hamster ovary cells — was approved by the FDA on 28 April 2006 under the brand name Myozyme, becoming the first disease-specific treatment for Pompe disease anywhere.

The trial that changed a death sentence

The pivotal evidence for Myozyme was an open-label study of 18 infants diagnosed with classic infantile-onset Pompe disease before 6 months of age, all treated with alglucosidase alfa. Every one of the 18 infants was alive at 18 months of age — a striking result against a well-documented natural history in which most infants with this form of the disease die within the first year without treatment — and a Cox proportional-hazards comparison against an untreated historical cohort found treatment reduced the risk of death or the need for invasive ventilation by 92% (Kishnani PS, Corzo D, Nicolino M, et al., "Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease," Neurology 2007;68(2):99-109, PMID 17151339, DOI: 10.1212/01.wnl.0000251268.41188.04).¹ Longer follow-up of the same cohort found invasive-ventilation-free survival of 66.7% at 24 months and 49.4% at 36 months — real, durable benefit in absolute terms, even though it shows treatment does not fully normalize outcomes for every infant in this most severe form of the disease. This evidence supported Myozyme's 2006 approval specifically for infantile-onset Pompe disease.

One enzyme, two brand names, and a manufacturing-scale problem

Myozyme was originally manufactured at a 160-liter bioreactor scale. As demand grew, Genzyme needed to manufacture the same enzyme at a much larger, 4,000-liter scale — but the FDA treats a sufficiently large change in a biologic's manufacturing process as potentially producing a meaningfully different product, requiring its own Biologics License Application rather than simply being folded into the existing one. Genzyme submitted that larger-scale version under a new brand name, Lumizyme, and the FDA approved it on 27 May 2010 — but only for late-onset Pompe disease in patients 8 years of age and older who did not have evidence of cardiac hypertrophy, with the smaller-scale Myozyme continuing to be the only approved option for infantile-onset disease and for late-onset patients under 8. The Lumizyme approval also came with a Risk Evaluation and Mitigation Strategy, the Lumizyme ACE (Alglucosidase Alfa Control and Education) Program, restricting distribution to that approved population and requiring enrollment by prescribers and infusion sites — a real regulatory outcome of treating a manufacturing-scale change as a distinct product, not a marketing choice.

This division of one enzyme into two differently-restricted brand names for close to four years is genuinely unusual: patients and prescribers had to track which brand was approved for which patient, based on age and disease subtype rather than any clinical difference in what was actually infused.

2014: one approval for every Pompe patient

On 1 August 2014, the FDA expanded Lumizyme's approval to cover all Pompe disease patients regardless of age or subtype, based on additional data Genzyme submitted supporting comparable safety and effectiveness across the full patient population, and eliminated the Lumizyme ACE REMS program entirely — healthcare providers, infusion sites and patients no longer needed to enroll in a restricted-distribution program to prescribe, dispense or receive the drug. Myozyme has continued to be marketed alongside Lumizyme since, with the two brand names now reflecting only which of Genzyme's manufacturing scales produced a given lot rather than any FDA-approved difference in who can receive it.

Current status

Both Myozyme and Lumizyme remain FDA-approved and currently marketed by Sanofi (through its Genzyme division). Alglucosidase alfa is no longer the only approved option: avalglucosidase alfa (Nexviazyme), an enzyme engineered for better uptake into muscle cells via the mannose-6-phosphate receptor pathway, was approved in 2021 for late-onset Pompe disease, and cipaglucosidase alfa paired with the oral enzyme stabilizer miglustat (Pombiliti plus Opfolda) was approved in 2023 for adults whose disease had not improved on existing enzyme-replacement therapy. Pompe disease, once uniformly fatal in its infantile form, now has a genuinely wider set of real, FDA-approved treatment options than existed when Myozyme first reached the market.